EN DE
Watch Procyon Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Procyon Corporation (PCYN) fair value: what the stock is really worth

As of Oct 27, 2026: fair value (intrinsic value) of Procyon Corporation stock $0.14, price $0.18, that is 22.2% below the price, quality 53 out of 100. Rating: overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PC Procyon Corporation logo Thin data Nov 7, 2026

Procyon Corporation

PCYN · US
Solid, but expensive

Our calculation puts a fair price 22% below what the stock costs today.

Low debt
Revenue last quarter +18% vs. a year ago.
Quality 53/100
Expensive Growth (revenue 5y +9.0 %/yr in USD)
Loss over the last twelve months · -6.8% net margin (TTM) · fiscal year 2025 0.5%
Mixed vs. peers (4/10)
Fair value $0.1400 · Overvalued
Negative free cash flow
Narrow moat 17/100
Thin data
⚠ Thinly traded
Watch Procyon Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.9500 $0.0013 Fair Value $0.1400 Jul 2015 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $0.0013 – $0.9500 · fair‑value band $0.1000 – $0.1800 · the $0.1800 price screens above the $0.1400 fair value. As of Nov 7, 2026.

Follow Procyon in your weekly email

Every Wednesday you see whether Procyon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Procyon Corporation, together with its subsidiaries, manufactures and markets wound and skin care products primarily in the United States.

Show moreShow less

It provides AMERIGEL, an advanced skin and wound care products, including hydrogel wound dressing, post op surgical kits, saline wound washes, and care and barrier lotions; HELIX3 Bioactive Collagen products, such as collagen powder, gel, and matrix; and calcium alginate dressing, foam dressing, amerx gauze dressing, hyrdocolloid dressing, as well as wound care kits, including calcium alginate, collagen matrix, collagen powder, foam, hydrogel, and rolled gauze wound care kits under the AMERX brand.

The company also offers AMERIGEL hand sanitizer; EXTREMIT-EASE compression garment products; Advantagen, a surgical collagen powder that promotes wound closure and reduces the potential for surgical site infection; calcium alginate, foam, and gauze dressings; retention tapes; and helix collagen gel.

It sells its products to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, physicians, and other health care practitioners; and retail customers through distributors, and direct and internet sales, as well as through independent and retail chain drug stores.

Procyon Corporation was incorporated in 1987 and is based in Oldsmar, Florida.

Stock analysis

Procyon Corporation (PCYN) currently trades at $0.1800, while our model-based Fair Value estimate is $0.1400, 22% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of $0.1900 per share, and 2 of the 10 models we run sit above the $0.1800 price.

Bear case: the Earnings-Based group reads lowest at $0.0300, and 8 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.1000 (bear) to $0.1800 (bull), the price of $0.1800 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Procyon Corporation reported revenue of $6.7M in FY2025 versus $4.7M in FY2021, a compound +9.0%/yr. Reported net income was $33.9K in FY2025, compounding −53.0%/yr from FY2021.

Key figures

Market cap $1.5M Micro · P/S ratio 0.29 · EPS (TTM) $−0.0600 · Net margin 0.5% · Return on equity −13.9% · Return on assets (EBIT) −4.8% (5-year average) · Operating margin 0.6% · Revenue (TTM) $5.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (medium confidence).

What moves the price

The share trades about 36% below its 52-week high and 49% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −22%, PCYN screens cheaper than that median.

Fair Value models

Bear $0.1000 Fair Value $0.1400 Bull $0.1800
Price $0.1800 · Downside -22.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $0.1000 $0.1400 $0.2000 77
Residual Income $0.1500 $0.1600 $0.1800 71
Growth-Adj P/E $0.0600 $0.0800 $0.1100 67
All 10 models by family
DCF Models
Owner Earnings $0.1000 $0.1400 $0.2000 77
Earnings-Based
Graham-Dodd $0.0300 $0.0900 $0.1300 64
Lynch FV $0.0200 $0.0300 $0.0400 61
PEG = 1.0 $0.0200 $0.0300 $0.0400 57
Multiples
P/E Multiple $0.0700 $0.0900 $0.1100 63
P/S Multiple $0.0500 $0.0700 $0.0900 58
P/B Multiple $0.1600 $0.2100 $0.2600 55
Asset-Based
NCAV (Graham) $0.1200 $0.1900 $0.2400 54
Economic Profit
Residual Income $0.1500 $0.1600 $0.1800 71
Growth Earnings
Growth-Adj P/E $0.0600 $0.0800 $0.1100 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 51
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 56
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 72
Distance to the 52-week high, does not count
New shares 55
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+33.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Start year 2020 (pandemic). Over 10 years: +9.2% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−21.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−21.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−21.4% vs −6.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → −7%
Pace: the 5-year rate starts in 2020 (pandemic)

PCYN screens overvalued: fair value 22% below the price. Compare with Merck KGaA →

Compare Procyon Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside −22.2% · Below median
Profitability
Return on assets 1.0% · Below median
Net margin (12 months) −6.8% · Bottom 25%
Operating margin (12 months) 0.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 17.5% · Above median
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.65× · Cheapest 25%
P/S (12 months) 0.31× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)4 · sector 15
FUTURE (revenue growth)88 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs PCYN
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs PCYN
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs PCYN
Haleon plc HLN $9.14 $8.61 −6% vs PCYN
Merck KGaA MRK €148.75 €109.18 −27% vs PCYN
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs PCYN
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs PCYN
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs PCYN
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs PCYN
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs PCYN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Procyon Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Procyon Corporation Fair Value". https://www.fairvalue-calculator.com/stock/PCYN

Frequently asked questions

Is Procyon Corporation (PCYN) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $0.1400 versus the last price from Oct 27, 2026 of $0.1800, about 22% lower (overvalued).
What is the fair value of PCYN?
Our model-based fair value for Procyon Corporation is $0.1400 (as of Nov 7, 2026), built from audited fundamentals. Last price (from Oct 27, 2026): $0.1800.
What is the quality score of PCYN?
Procyon Corporation has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Procyon Corporation (PCYN)?
Our model-based price target is the fair value of $0.1400 (as of Nov 7, 2026) from 10 valuation models. Cautious scenario $0.1000, optimistic scenario $0.1800. It is a calculation from audited fundamentals, not an analyst target.
What is the Procyon Corporation stock forecast for 2026?
Our models put fair value at $0.1400, about 22% lower versus the last price from Oct 27, 2026 of $0.1800 (overvalued). Cautious scenario $0.1000, optimistic scenario $0.1800. The calculation is refreshed regularly with new filings.
What is the revenue of Procyon Corporation (PCYN)?
Procyon Corporation reported trailing-twelve-month revenue of about $5.0M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Procyon Corporation (PCYN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Procyon Corporation it is $0.1400 per share (as of Nov 7, 2026), against a price of $0.1800. It is the blended result of 10 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Procyon Corporation stock overvalued or undervalued in 2026?
As of Nov 7, 2026, PCYN trades above its calculated fair value: price $0.1800, fair value $0.1400, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PCYN?
No. The price is what the market pays today ($0.1800); the fair value is what the company's own numbers justify ($0.1400). For Procyon Corporation the two are $0.0400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Procyon Corporation worth?
The market values Procyon Corporation at about $1.5M (market capitalisation, as of Nov 7, 2026). Per share that is $0.1800; our models calculate a fair value of $0.1400 per share.
What do the bullish and bearish scenarios say about PCYN?
Our models span a range for Procyon Corporation: cautious scenario $0.1000, base $0.1400, optimistic $0.1800 per share (as of Nov 7, 2026, price $0.1800). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Procyon Corporation (PCYN)?
Balance-sheet figures for Procyon Corporation (as of Nov 7, 2026): return on equity −13.9%, debt of 0.06 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is PCYN from its 52-week high?
Procyon Corporation trades at $0.1800, about 36% below its 52-week high of $0.2800 and 49% above the low of $0.1210 (as of Oct 27, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1400 is for.
Which stocks are comparable to Procyon Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Procyon Corporation stock attractive at the current price?
The data as of Nov 7, 2026: price $0.1800, calculated fair value $0.1400 (−22%), Quality Score 53/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PCYN calculated?
We run Procyon Corporation through 10 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.1400 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Procyon Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Procyon Corporation (PCYN)?
The latest price we hold is from Oct 27, 2026 and stands at $0.1800. Our model-based fair value is $0.1400, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Procyon Corporation right now?
Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Procyon Corporation

How large is the market capitalisation of Procyon Corporation (PCYN)?
The market capitalisation of Procyon Corporation is $1.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Procyon Corporation (PCYN)?
The price-to-sales ratio of Procyon Corporation is 0.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Procyon Corporation (PCYN)?
Earnings per share at Procyon Corporation are $−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Procyon Corporation (PCYN)?
The net margin of Procyon Corporation is 0.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Procyon Corporation (PCYN)?
The return on equity (ROE) of Procyon Corporation is −13.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Procyon Corporation (PCYN)?
On an EBIT basis the return on assets of Procyon Corporation is −4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Procyon Corporation (PCYN)?
The operating margin of Procyon Corporation is 0.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Procyon Corporation (PCYN)?
Revenue at Procyon Corporation is growing +17.5% versus a year earlier (3y avg +11.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Procyon Corporation (PCYN)?
Earnings per share at Procyon Corporation are growing −82.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Procyon Corporation (PCYN) generate?
The free cash flow of Procyon Corporation is −$495K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Procyon Corporation (PCYN) carry?
The net debt of Procyon Corporation is $58.5K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Procyon Corporation in the live analysis

One click puts Procyon Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.